Enzymotec Ltd. (NASDAQ:ENZY) announced its earnings results on Wednesday. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by $0.15, Morningstar.com reports. Enzymotec had a negative net margin of 9.50% and a negative return on equity of 2.06%. The company had revenue of $13 million during the quarter, compared to analyst estimates of $12.78 million. During the same quarter last year, the business earned $0.04 EPS. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year.

Shares of Enzymotec (NASDAQ:ENZY) traded down 0.6651% during mid-day trading on Wednesday, hitting $10.2315. 6,613 shares of the stock traded hands. Enzymotec has a 12-month low of $5.20 and a 12-month high of $10.55. The firm’s 50 day moving average price is $8.35 and its 200 day moving average price is $8.50. The firm’s market cap is $234.29 million.

Several brokerages have recently issued reports on ENZY. Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Friday, April 28th. ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a sell rating and three have issued a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $8.00.

WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/enzymotec-ltd-enzy-releases-quarterly-earnings-results-misses-expectations-by-0-15-eps/1494670.html.

Institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC bought a new position in Enzymotec during the second quarter worth $2,350,000. Renaissance Technologies LLC boosted its position in Enzymotec by 12.3% in the fourth quarter. Renaissance Technologies LLC now owns 290,000 shares of the biotechnology company’s stock worth $1,900,000 after buying an additional 31,700 shares during the period. Acadian Asset Management LLC boosted its position in Enzymotec by 3.2% in the first quarter. Acadian Asset Management LLC now owns 237,184 shares of the biotechnology company’s stock worth $2,088,000 after buying an additional 7,322 shares during the period. State of New Jersey Common Pension Fund D boosted its position in Enzymotec by 12.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 28,110 shares of the biotechnology company’s stock worth $247,000 after buying an additional 3,113 shares during the period. Finally, State Street Corp boosted its position in Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after buying an additional 380 shares during the period. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Earnings History for Enzymotec (NASDAQ:ENZY)

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.